Edward Stadtmauer, MD
Enriched profileRoseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor; Director of Hematologic Malignancies Clinical/Translational Research, Division of Hematology-Oncology · University of Pennsylvania
Edward Stadtmauer is Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor; Director of Hematologic Malignancies Clinical/Translational Research, Division of Hematology-Oncology at University of Pennsylvania. OpenAlex indexes 630 publications with 36,500 citations (h-index 88); ClinicalTrials.gov lists 7 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Edward A. Stadtmauer, MD, is Roseman, Tarte, Harrow, and Shaffer Families' President's Distinguished Professor at University of Pennsylvania, Perelman School of Medicine / Abramson Cancer Center, Division of Hematology-Oncology. The public record shows 630 publications with 36,500 citations (h-index 88), centered on Hematology. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 10 companies, 7 NIH-funded awards (1999–2026).
- Most recent indexed publication: 2024 · bioRxiv
- Top research focus: Hematology
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma
Sponsor: Abramson Cancer Center at Penn Medicine
- Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
Sponsor: Sorrento Therapeutics, Inc.
- NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Sponsor: University of Pennsylvania
Industry payments
Updated 14 Oct 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20259 payments
- GENZYME CORPORATIONProgram year20252 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65.4%Thalidomide Analog60.9%Lenalidomide43%Revlimid30%Pomalyst27%Part D≥37 patientsLeukocyte Growth Factor2.6%Zarxio100%Part D≥11 patients+ 1 more class in this area
Anti-infectives
15.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor9.7%Valacyclovir100%Part D≥22 patientsMacrolide Antimicrobial2.9%Azithromycin100%Part D≥12 patients+ 2 more classes in this area
Nervous system
7.1%SSRI3%Escitalopram Oxalate100%Part D<11 patientsOpioid Agonist2.3%Oxycodone Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
7 NIH research awards on record, funded 1999–2026 per NIH RePORTER. The latest:
- BMT CTN Core- University of Pennsylvania Abramson Cancer Center
University of Pennsylvania
FY2026$236,002UG1HL069286 - BMT CTN Core- University of Pennsylvania Abramson Cancer Center
University of Pennsylvania
FY2025$239,933UG1HL069286
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Blood cancer discovery
Article2023 - Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.
Blood cancer discovery
Comment2022 - CRISPR-engineered T cells in patients with refractory cancer.
Science (New York, N.Y.)
Clinical Trial2020
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- ResearchGate
researchgate.net/scientific-contributions/Edward-A-Stadtmauer-39464686
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗ - X / Twitter
x.com/pennmdforum/status/956882061889101824
- Facebook
m.facebook.com/TheASCOPost/videos/edward-a-stadtmauer-md-on-advanced-multiple-myeloma-and-sarcoma-first-in-human-a/290475125190178
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →m.facebook.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
- Residency
Albert Einstein College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗ - Hematology-Oncology Fellowship
University of Pennsylvania Health System
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →79classmates.net ↗
- Co-Leader
Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Co-Leader
Hematologic Malignancies Translational Center of Excellence, Penn Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Director of Hematologic Malignancies Clinical/Translational Research
Division of Hematology-Oncology, Penn
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Editorial board member
Journal of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →79classmates.net ↗ - Editorial board member
Bone Marrow Transplantation (Nature)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →79classmates.net ↗ - Co-Chairman
Bone Marrow Transplant Committee, Eastern Cooperative Oncology Group (ECOG) (10 years)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗ - Leadership roles with Center for International Bone Marrow Transplant Research (CIBMTR): chair of nominating committee
co-chair Solid Tumor Working Committee, member Clinical Trials Advisory Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗ - Member
Career Development Award Selection Committee, Leukemia & Lymphoma Society
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pennmedicine.org ↗
- DuPont Guerry
IV, MD Award for Outstanding Mentorship (Penn Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →79classmates.net ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →79classmates.net ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →79classmates.net ↗
Secondary affiliations
appointments beyond the home institution- Member
Penn Center for Myeloproliferative Neoplasms
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗ - Advisor/collaborator
Parker Institute for Cancer Immunotherapy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →parkerici.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →treatingbloodcancers.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curetalks.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
Nabila Dahodwala, MD
University of Pennsylvania
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center